bioRxivSystems BiologyPreprint
Heterogeneous, Population-Level Drug-Tolerant Persisters Exhibit Ion-Channel Remodeling and Ferroptosis Susceptibility
Corey E. HayfordiD, Blake Baleami, Philip E. StaufferiD, B. Bishal PaudeliD, Aziz M. Al’KhafajiiD, Amy BrockiD, Vito QuarantaiD, Darren R. TysoniD, Leonard A. HarrisiD
- Citations
- 3
Abstract
Drug-tolerant persisters (DTPs) represent a major obstacle to durable responses in targeted cancer therapy. DTPs are commonly described as distinct single-cell states that survive drug treatment via reversible, non-genetic mechanisms and drive tumor recurrence. Recent work demonstrates that multiple DTPs can coexist, reflecting diversity in lineage, signaling programs, or stress responses. However, each DTP is still generally viewed as a uniform cellular phenotype. Building on our prior work describing a population-level DTP termed "idling" [Paudel et al., Biophys. J. (2018) 114, 1499-1511], here we present evidence supporting a fundamentally different view: that DTPs are not single-cell states, but rather heterogeneous populations composed of multiple sub-states with distinct division and death rates that balance to produce near-zero net population growth. Using single-cell transcriptomics and lineage barcoding, we identify multiple phenotypic states within idling DTP populations, with reduced heterogeneity compared to untreated populations, and find that idling DTP cells emerge from nearly all lineages. Transcriptomic and functional analyses further reveal altered ion-channel activity in idling DTPs, which we confirm experimentally. Moreover, drug-response assays reveal increased susceptibility of idling DTPs to ferroptosis, a non-apoptotic form of regulated cell death, indicating the emergence of vulnerabilities associated with drug tolerance. Altogether, our results support a population-level view of tumor drug tolerance in which DTPs comprise stable collections of phenotypic states, shaped by treatment-defined phenotypic landscapes, which are potentially vulnerable to subsequent interventions. This perspective implies that eradicating DTPs will require a fundamental shift away from cell-type-centric strategies toward sequential treatments that progressively reduce phenotypic heterogeneity by modulating the molecular and cellular processes that establish the DTP landscape, an approach previously termed "targeted landscaping."
- organism: human
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- research focus: benchmarking
- approach: statistical model
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Drug tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms
Maria Davern, Cole J. Turner, … Anthony G. Letai·Cell Death and DifferentiationPeer-reviewed·Dec 26, 2025
- Inheritable cell-states shape drug-persister correlations and population dynamics in cancer cells
Anton Iyer, Adrian Alva, … Shaon Chakrabarti·PLoS Computational BiologyPeer-reviewed·Sep 19, 2025
- Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer
C. A. Chang, J. Jen, … B. G. Neel·bioRxiv·Aug 28, 2020
- Chemotherapy-induced multicellularity drives drug-tolerant persistence state in tumor cells
Jing Li, Z G Zhu, … Chunfang Liu·bioRxiv·Jul 10, 2026
- Drug-tolerant persister cells reallocate carbon sources to fuel antioxidant metabolism for survival
Melvin Li, Bradley Priem, … Sarah R. Amend·bioRxiv·Jan 6, 2026
- Transcriptional landscape of DTP-DTEP transition reveals DUSP6 as a driver of HER2 inhibitor tolerance via Neuregulin/HER3 axis
M. Momeny, M. Tienhaara, … J. Westermarck·bioRxiv·Jun 14, 2023